Literature DB >> 27197167

MYC Is a Crucial Mediator of TGFβ-Induced Invasion in Basal Breast Cancer.

Magdalena A Cichon1, Megan E Moruzzi1, Tiziana A Shqau1, Erin Miller1, Christine Mehner1, Stephen P Ethier2, John A Copland1, Evette S Radisky1, Derek C Radisky3.   

Abstract

Basal subtype breast cancers have a particularly poor prognosis, with high invasiveness and resistance to most targeted therapies. TGFβ and MYC drive central features of basal breast cancer: TGFβ is an autocrine and paracrine signaling factor that drives cell invasion and metastasis, and MYC is a central regulator of cellular proliferation that is upregulated in many cancer types. We show here that genetic or pharmacologic inhibition of MYC in MCF10A basal breast cells results in increased sensitivity to TGFβ-stimulated invasion and metastasis and also show that this signaling loop is dependent on activation of SRC. Analysis of human breast cancer datasets and additional experiments with breast cancer cell lines further suggest the relevance of this signaling loop in basal, but not luminal, breast cancers. Our results imply precaution should be taken when utilizing therapeutic inhibitors of MYC with basal breast cancer patients as this could lead to increased metastasis; however, simultaneous pharmacologic inhibition of SRC and MYC for these patients could facilitate the antiproliferative effects of MYC inhibition while blocking the consequent promotion of metastasis. Cancer Res; 76(12); 3520-30. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197167      PMCID: PMC4911305          DOI: 10.1158/0008-5472.CAN-15-3465

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

1.  Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program.

Authors:  C R Chen; Y Kang; J Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

2.  Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.

Authors:  Jona A Hattangadi-Gluth; Jennifer Y Wo; Paul L Nguyen; Rita F Abi Raad; Meera Sreedhara; Andrzej Niemierko; Phoebe E Freer; Dianne Georgian-Smith; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-19       Impact factor: 7.038

Review 3.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

4.  A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer.

Authors:  Erica L Mayer; Jean-Francois Baurain; Joseph Sparano; Lewis Strauss; Mario Campone; Pierre Fumoleau; Hope Rugo; Ahmad Awada; Oumar Sy; Antonio Llombart-Cussac
Journal:  Clin Cancer Res       Date:  2011-09-08       Impact factor: 12.531

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

Review 6.  TGFbeta in Cancer.

Authors:  Joan Massagué
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

7.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

8.  GS domain mutations that constitutively activate T beta R-I, the downstream signaling component in the TGF-beta receptor complex.

Authors:  R Wieser; J L Wrana; J Massagué
Journal:  EMBO J       Date:  1995-05-15       Impact factor: 11.598

9.  GOBO: gene expression-based outcome for breast cancer online.

Authors:  Markus Ringnér; Erik Fredlund; Jari Häkkinen; Åke Borg; Johan Staaf
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

10.  Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.

Authors:  Aleix Prat; Olga Karginova; Joel S Parker; Cheng Fan; Xiaping He; Lisa Bixby; J Chuck Harrell; Erick Roman; Barbara Adamo; Melissa Troester; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2013-10-27       Impact factor: 4.872

View more
  6 in total

1.  Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis.

Authors:  Ekta Agarwal; Brian J Altman; Jae Ho Seo; Irene Bertolini; Jagadish C Ghosh; Amanpreet Kaur; Andrew V Kossenkov; Lucia R Languino; Dmitry I Gabrilovich; David W Speicher; Chi V Dang; Dario C Altieri
Journal:  Mol Cell Biol       Date:  2019-06-27       Impact factor: 4.272

Review 2.  Metastasis suppressors: functional pathways.

Authors:  Imran Khan; Patricia S Steeg
Journal:  Lab Invest       Date:  2017-10-02       Impact factor: 5.662

3.  Hepsin regulates TGFβ signaling via fibronectin proteolysis.

Authors:  Topi A Tervonen; Juha Klefström; Denis Belitškin; Shishir M Pant; Pauliina Munne; Ilida Suleymanova; Kati Belitškina; Hanna-Ala Hongisto; Johanna Englund; Tiina Raatikainen; Olga Klezovitch; Valeri Vasioukhin; Shuo Li; Qingyu Wu; Outi Monni; Satu Kuure; Pirjo Laakkonen; Jeroen Pouwels
Journal:  EMBO Rep       Date:  2021-09-13       Impact factor: 8.807

4.  MYC overexpression with its prognostic and clinicopathological significance in breast cancer.

Authors:  Jingkun Qu; Xixi Zhao; Jizhao Wang; Xu Liu; Yan Yan; Lin Liu; Hui Cai; Hangying Qu; Ning Lu; Yuchen Sun; Feidi Wang; Jiansheng Wang; Jia Zhang
Journal:  Oncotarget       Date:  2017-10-05

5.  ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.

Authors:  Anieta M Sieuwerts; Márcia A Inda; Marcel Smid; Henk van Ooijen; Anja van de Stolpe; John W M Martens; Wim F J Verhaegh
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

6.  Cancer stem cell property and gene signature in bone-metastatic Breast Cancer cells.

Authors:  An Luo; Yue Xu; Shujun Li; Jinxia Bao; Jinhui Lü; Nan Ding; Qian Zhao; Yuting Fu; Fei Liu; William C Cho; Xunbin Wei; Haiyun Wang; Zuoren Yu
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.